WLLW vs. MDP, VIR, ZOM, CWEB, IN, META, LABS, DB, NRTH, and MRV
Should you be buying Willow Biosciences stock or one of its competitors? The main competitors of Willow Biosciences include Medexus Pharmaceuticals (MDP), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), Charlotte's Web (CWEB), InMed Pharmaceuticals (IN), Meta Growth (META), MediPharm Labs (LABS), Decibel Cannabis (DB), 48North Cannabis (NRTH), and Nuvo Pharmaceuticals (MRV). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Medexus Pharmaceuticals (TSE:MDP) and Willow Biosciences (TSE:WLLW) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.
In the previous week, Willow Biosciences' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.
Willow Biosciences received 13 more outperform votes than Medexus Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Medexus Pharmaceuticals an outperform vote while only 82.35% of users gave Willow Biosciences an outperform vote.
Medexus Pharmaceuticals has higher revenue and earnings than Willow Biosciences. Willow Biosciences is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Medexus Pharmaceuticals has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Willow Biosciences has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.
8.4% of Medexus Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Willow Biosciences shares are held by institutional investors. 8.7% of Medexus Pharmaceuticals shares are held by company insiders. Comparatively, 27.3% of Willow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Medexus Pharmaceuticals has a net margin of 5.08% compared to Medexus Pharmaceuticals' net margin of 0.00%. Willow Biosciences' return on equity of 26.14% beat Medexus Pharmaceuticals' return on equity.
Summary
Medexus Pharmaceuticals beats Willow Biosciences on 11 of the 14 factors compared between the two stocks.
Get Willow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WLLW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WLLW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Willow Biosciences Competitors List
Related Companies and Tools
